Table 1 Experimental groups and vaccine types utilized in this study
Groups (30 bird per group) | Vaccine | Challenge at 51 days old (0.1 ml Intraocular) | Note |
|---|---|---|---|
Group 1(N) | Not vaccinated | Not challenged | Control negative |
Group 2(CS) | Not vaccinated | 104 TCID50/ml | Challenged with CEO like strain |
Group 3(RS) | Not vaccinated | 104 TCID50/ml | Challenged with Recombinant strain |
Group 4 (VEC + CS) | Innovax-ILTa | 104 TCID50/ml CEO like strain | Vaccinated and challenged |
Group 5(VEC + RS) | Innovax-ILTa | 104 TCID50/ml recombinant strain | Vaccinated and challenged |
Group 6(CEO + CS) | CEO vaccineb (Trachivax) | 104 TCID50/ml CEO like strain | Vaccinated and challenged |
Group 7(CEO + RS) | CEO Vaccineb (Trachivax) | 104 TCID50/ml recombinant strain | Vaccinated and challenged |
Group 8(TCO + CS) | TCO Vaccineb (LT-IVAX) | 104 TCID50/ml CEO like strain | Vaccinated and challenged |
Group 9(TCO + RS) | TCO Vaccineb (LT-IVAX) | 104 TCID50/ml recombinant strain | Vaccinated and challenged |